We examined c-erbB3 and c-erbB4 mRNA expression in 47 primary breast cancer samples by simultaneous RT ± PCR and have investigated correlations between these parameters and the expression of both ER and EGFR mRNA and protein as measured by RT ± PCR and ICA and with Ki67 immunostaining. A direct association was found between c-erbB3 and c-erbB4 mRNA and ER marker status measured by either RT ± PCR (c-erbB3 P=0.0003; c-erbB4 P=0.02) or ICA (c-erbB-3 P=0.002; c-erbB4 P=0.01). Inverse associations were seen between c-erbB3 and c-erbB4 mRNA marker status and EGFR membrane protein (c-erbB3: P=0.003; cerbB4: P=0.003) and mRNA (c-erbB4: P=0.009) status. These associations were reinforced by Spearman Rank Correlation Tests. A signi®cant relationship was seen between Ki67 and c-erbB4 mRNA status and level. Measurements of c-erbB3 protein levels in tumour samples removed from a further 89 patients of known response to endocrine therapy: (i) con®rmed the relationship between c-erbB3 and ER and (ii) identi®ed that patients whose ER positive tumours expressed high levels of c-erbB3 were most likely to bene®t from endocrine measures. A non-signi®cant trend was recorded between c-erbB3 levels and Ki67 immunostaining. These results clearly demonstrate that increased c-erbB3 and c-erbB4 expression appears to be associated with the prognostically-favourable ER phenotype.
Introduction
The sensitivity of breast cancer growth to steroid hormones has been exploited clinically by the use of antihormonal agents (notably tamoxifen) which can bring about disease regression (Nicholson et al., 1992; . Unfortunately, not all patients respond (de novo resistance) and the majority of initial responders eventually relapse following acquisition of endocrine resistance (Wolf and Jordan, 1993; Osborne et al., 1991; Nicholson and Gee, 1996; Gee et al., 1996) . An understanding of the processes involved in these phenomena is obviously essential not only to enable better patient strati®cation for treatment, but also to allow the development of more eective therapeutic agents targeted to aberrant cellular pathways.
Our investigations using immunocytochemistry have revealed that changes in growth factor pathways, notably those using the epidermal growth factor receptor (EGFR) and c-erbB2 (Nicholson et al., 1993 may be an important factor in the subversion of clinical endocrine response. These proteins belong to the type 1 sub-group of receptor tyrosine kinases which also contains c-erbB3 and c-erbB4 (Rajkumar and Gullick, 1994; Gullick, 1996) and which share common molecular structures comprising an extracellular ligand binding domain with two cysteine rich sequences, a short transmembrane domain and an intracellular tyrosine kinase domain¯anked by a hydrophilic tail of varying length which carries several tyrosine phosphorylation sites (Fantl et al., 1993; Peles et al., 1993; Plowman et al., 1993a) . Signal transduction through type 1 receptor tyrosine kinases is initiated by ligand-induced stabilisation of receptor dimers followed by receptor autophosphorylation and recruitment of speci®c signalling proteins containing Src homology 2 (SH2) domains. Speci®c sets of SH2-containing proteins associate with dierent receptor dimers, thereby giving rise to a broad spectrum of downstream signalling events Riese et al., 1995) .
EGFR binds several distinct ligands including EGF and TGFa (Prigent and . No ligand has yet been identi®ed which binds directly to c-erbB2. Both c-erbB3 and c-erbB4 bind a range of ligands of which the splice variants of neuregulin (heregulin, neu dierentiation factor) have received particular attention (Riese et al., 1995) . Despite the absence of a direct ligand, transphosphorylation of c-erbB2 can be induced following heterodimerisation to ligand-bound c-erbB3 or c-erbB4 (Tzahar et al., 1996) . c-erbB2 is the preferred partner for heterodimerization and when co-expressed with either EGFR or c-erbB3, synergistically enhances their mitogenic and transforming activity (Tzahar et al., 1996) . Along with dierences in ligand binding each member of this sub-group has a dierent intrinsic tyrosine kinase activity i.e. c-erbB2 has a constitutively active tyrosine kinase activity (Lonardo et al., 1990) , whereas c-erbB3 is catalytically inactive (Guy et al., 1994) .
Over expression of the EGFR and c-erbB2 receptors in breast cancer has been demonstrated in a number of studies to be associated with ER negativity, elevated tumour cell proliferation rates, lack of endocrine response and poor patient prognosis (Nicholson et al., 1993 Klijn et al., 1992; Slamon et al., 1987) . Over expression of both c-erbB3 in some breast tumours (Gasparini et al., 1994; Lemoine et al., 1992) and c-erbB4 in some cell lines (Plowman et al., 1993b) has been previously reported. However the frequency of their expression in ER positive and ER negative disease is as yet unknown, as is their eect (if any) on clinical endocrine response. In this study, we have examined the expression of ER, EGFR, c-erbB3 and cerbB4 mRNA levels by semi-quantitative RT ± PCR, in addition to protein levels for ER, EGFR, c-erbB3 and Ki67 using immunocytochemistry in primary breast cancer clinical specimens. We have investigated the correlations between these parameters and furthermore assessed how c-erbB3 protein expression relates (i) to patient response to endocrine therapy and (ii) to expression of the proliferation marker Ki67.
Results
In this study, two groups of breast tumours were used (one series comprised of 47 and the other series 89 tumours) having been excised from patients with histologically-proven breast cancer (see Materials and methods).
Simultaneous RT ± PCR reactions were performed on Total RNA from each of the 47 tumours of group 1, in all cases using a combination of primers for aactin as an internal standard and primers for either ER, EGFR, c-erbB3 or c-erbB4. RT ± PCR was also performed using speci®c c-erbB2 primers, but data regarding this marker are not included in the present study as no correlations were observed with the range of parameters examined.
Preliminary experiments were undertaken to fully optimise the RT ± PCR procedure, determining that the most eective cycle number for each of the primer sets was 27. The developed RT ± PCR procedure for the detection of c-erbB3 and c-erbB4 mRNA was tested further using a small sub-group of breast tumour samples and was found to be highly reproducible, with a mean densitometry variance of only *4% (not illustrated). Furthermore, analysis of c-erbB3 mRNA expression by RT ± PCR for a series of breast cancer cell lines was in concurrence with the literature, both for those reported as positive (ZR75.1, MCF-7, MDA 453; Lemoine et al., 1992; Kraus et al., 1993; Chan et al., 1995) and negative (MDA 231, A431; Rajkumar and Gullick, 1994) respectively for c-erbB3 mRNA and protein (not illustrated).
Representative results obtained for 20 of the 47 group 1 samples with these primers are illustrated in Figure 1 . The amount of product detected for each of the four mRNA species being examined varied considerably among the tumour samples. This variation in product levels was maintained following normalisation to the aactin internal control by scanning densitometry indicating the variation was most likely to be tumour speci®c. A standard of 27 cycles was chosen for all primer sets, as this cycle number was found to be in the linear range for ampli®cation for each mRNA species (see Materials and methods), in agreement with previously established conditions (Knowlden et al., 1997) . In addition, this cycle number was found to show the greatest degree of product variation between specimens. An immunocytochemical analysis of the samples for nuclear ER and membrane associated EGFR showed positive immunostaining in breast cancer epithelial cells in 55% and 45% of the tumours respectively (not illustrated).
Using the appropriate cut-o points (see Materials and methods), a statistical analyses of the data using Fisher's Exact Test (Table 1) , showed a highly signi®cant positive association between c-erbB3 and c-erbB4 mRNA marker status as determined by RT ± PCR, and both ER mRNA (c-erbB3: P=0.0003; c-erbB4: P=0.02 for 47 tumour samples and ER protein status (c-erbB3: P=0.002; c-erbB4: P=0.01) (46 tumour samples). Approximately 70% of tumours positive for ER protein or mRNA co-expressed cerbB3 or c-erbB4, while only 30% of patients with ER negative tumours expressed these growth factor receptors. Conversely, there was a highly signi®cant inverse relationship between c-erbB3 and c-erbB4 mRNA marker status and the EGFR protein (cerbB3: P=0.003; c-erbB4: P=0.003) for 44 tumour samples and mRNA status (c-erbB4: P=0.009) for 47 tumour samples. Only approximately 30% of tumours positive for EGFR protein or mRNA co-expressed cerbB3 or c-erbB4, while 70% of EGFR negative cancers expressed these receptors.
Application of the Spearman Rank Correlation Test to this data also indicated a positive correlation between the levels of normalized c-erbB3 and c-erbB4 mRNA as determined by RT ± PCR and both ER mRNA (c-erbB3: r=0.51, P=50.001, not illustrated; c-erbB4: r=0.52, P=50.001; Figure 2a ) and ER protein ICA Hscores (c-erbB3: r=0.55, P=50.001, not illustrated; c-erbB4: r=0.37, P=0.01, not illustrated). There was also a signi®cant inverse correlation between levels of normalized c-erbB3 and c-erbB4 mRNA as determined by RT ± PCR and the EGFR membrane protein ICA HScores (c-erbB3: r=70.42, P=0.005, not illustrated and c-erbB4: r=70.62, P=50.001; Figure 2b ), although only the inverse association observed between c-erbB4 mRNA level and EGFR mRNA reached signi®cance (r=70.35, P=0.02, not illustrated). Further statistical analysis Figure 1 Ethidium bromide gels obtained following RT ± PCR (27 cycles) of 20 primary breast tumours. Speci®c primer sets were used for ER, EGFR, c-erbB3 and c-erbB4 and were co-ampli®ed with speci®c primers for aactin (* denotes the aactin band). RT ± PCR mRNA status was determined after a densitometric analysis of the gels and normalization of the ER and c-erbB family members to aactin. Samples were designated negative (0) or positive (1) using the Fisher's Exact Test on this data showed that there was an inverse association between Ki67 (marker of proliferation) protein and c-erbB4 mRNA (P=0.03). This was reinforced by Spearman Rank Correlation Test (P=0.046).
Prior to the analysis of the levels of c-erbB3 staining in clinical breast cancer specimens, the pro®ciency of the optimised immunocytochemical assay using the RTJ1 antibody (Rajkumar et al., 1993) for detection of c-erbB3 in a series of breast cancer cell monolayers (see Materials and methods) was undertaken. As for the mRNA, status levels of c-erbB3 protein were found to be in agreement with those reported in the literature as positive (ZR75.1, MCF-7, MDA 453; Lemoine et al., 1992; Kraus et al., 1993) or negative (MDA 231, A431 Rajkumar and Gullick, 1994) respectively for c-erbB3 protein (not illustrated). Having thus standardized the conditions of the assay, an immunocytochemical analysis of c-erbB3 in group 2 primary breast cancer specimens revealed membrane immunostaining in 84% specimens. Levels of staining, however, were highly variable and only 37% (33/89) of samples had HScore values above 1 (Table 2) . A statistical analysis using w 2 Test showed a signi®cant positive association between ER marker status and c-erbB3 marker status (w 2 =13, 2 d.f., P=0.001). This was further quali®ed by the application of the Spearman Rank Correlation Test to this data (P=0.011). Thus while 23/51 (45%) ER positive cancers showed high levels of the c-erbB3 protein, only 10/38 (26%) ER negative tumours showed similar characteristics. In contrast, only 2/14 c-erbB3 negative samples were ER positive. Examina- Table 1 Comparison of ER, EGFR, c-erbB3 and c-erbB4 marker status generated by dierent technologies in breast cancer specimens
c-erbB4 RT ± PCR (0) c-erbB4 RT ± PCR (1) 13 (28%) 3 (7%) 12 (26%) 18 (39%)
EGFR RT ± PCR (0) EGFR RT ± PCR (1) c-erbB3 RT ± PCR (0) c-erbB3 RT ± PCR (1) 10 (21%) 16 (34%) 10 (21%) 11 (23%)
17 ( tion of the degree of Ki67 immunostaining in all patients identi®ed a statistically signi®cant relationship between c-erbB3 membrane status levels and decreasing Ki67 positivity (Figure 3a ; Mann-Whitney U Test, P=0.008), although some overlap existed within each sub-group. For the ER positive and ER negative patient sub-groups a non-signi®cant trend (P=0.26, P=0.09 respectively) was evident between the c-erbB3 status levels and decreasing Ki67 positivity as illustrated in Figure 3b and c. An evaluation of the initial endocrine responsiveness of the group 2 set of tumours in relation to their ER and c-erbB3 levels showed that while the majority of patients with ER negative tumours progressed on endocrine therapy, independent of their c-erbB3 status, in ER+ve disease high c-erbB3 immunostaining was frequently associated with clinically worthwhile remissions (Table 3) . Patients whose tumours were ER positive, but contained only moderate levels of cerbB3 (category 1), showed a response rate intermediate between ER positive/highly c-erbB3 positive and ER negative disease. An almost statistically signi®cant association was observed in ER+tumours between increasing c-erbB3 levels and endocrine sensitivity comparing categories 1 and 2 (w 2 =9.1, 4 d.f., P=0.06). These correlations were also re¯ected in the survival characteristics of all patients (Figure 4 ) with, for example, mean survival times of 17.1, 30.3 and 39 months recorded for c-erbB3 negative, moderately positive and highly positive samples respectively (Generalised Wilcoxin Test 9.33, 2 d.f., P=0.009).
Examination of the mean c-erbB3 mRNA signal as well as the c-erbB3 protein immunostaining revealed a high signal intensity using both procedures in the very small series of tumour-associated normal breast samples available for study (i.e. n=7 and n=11 respectively). While positivity was similarly prominent in ER+ve endocrine responsive breast cancers as stated above, the normal breast signal was observed to exceed that associated with ER7ve tumours by approximately 40% (not illustrated).
Discussion
Extensive studies have demonstrated an inverse association between the expression of the ER, the cellular mediator of the growth promoting actions of oestrogens, and the expression of either the EGFR or c-erbB2 (Nicholson et al., 1993 . Consequently, the expression of the latter proteins has been linked to de novo endocrine insensitivity (Nicholson et al., 1993) . Importantly, however, these proteins do not appear to be just additional markers of loss of endocrine response in ER negative breast cancer, rather their levels have been shown to be directly linked to the prevailing proliferative index of the tumours (Nicholson et al., 1993) , inferring a causal relationship and identifying them as potential targets for anti-growth factor regimes . In the present study we have questioned whether other erbB family members, namely c-erbB3 and c-erbB4, might (i) also show the same relationship with ER, (ii) reinforce proliferative signals to breast cancer cells when overexpressed and (iii) divert endocrine sensitivity. In what manner do the cellular levels of c-erbB3 and c-erbB4 relate to ER (and EGFR)?
Our study initially examined this question by analysing the cellular levels of ER, EGFR, c-erbB3 and c-erbB4 mRNA using a semi-quantitative RT ± PCR procedure.
In 47 primary breast cancers we observed a statistically signi®cant positive association between c-erbB3/c-erbB4 mRNA marker status/levels and ER mRNA marker status/levels. Relationships of similar statistical signi®cance were also evident when c-erbB3/c-erbB4 mRNA status/levels were compared to ER protein levels, as determined by immunocytochemistry.
Although it is noteworthy that virtually all samples showed some level of c-erbB3 and c-erbB4 mRNA positivity using the RT ± PCR procedure, nevertheless, the results demonstrate a marked divergence from previous studies noting an inverse relationship between the EGFR and ER (Nicholson et al., 1993 ) and c-erbB3 and ER (Brotherick et al., 1995) . Indeed, in support of such divergent behaviour, our study has demonstrated an inverse association between c-erbB3 and c-erbB4 mRNA marker status/levels and EGFR membrane protein and mRNA marker status/levels. Discrepant results, such as in the cases of complete ER negativity where often c-erbB3 and c-erbB4 mRNA positivity was observed, may have their roots in diering procedural sensitivities (Daada et al., 1994) . Similarly, our failure to previously obtain a relationship between c-erbB3 and ER results from procedural modi®cations of the c-erbB3 assay which now allows the detection of c-erbB3 membrane immunostaining in addition to the detection of c-erbB3 cytoplasmic immunostaining. Clearly, signi®cant levels of c-erbB3/c-erbB4 mRNA expression in clinical material are most likely to be found in ER positive/EGFR negative disease, a tumour phenotype which has previously been related to many good prognostic features in breast cancer, including initial endocrine responsiveness, well-dierentiated pathological features and reduced cellular proliferative capacity (Nicholson et al., 1993 . Indeed, our immunocytochemical ®ndings utilising the c-erbB3 antibody reinforce the positive relationship between cerbB3 and ER.
In what manner do the cellular levels of c-erbB3 and c-erbB4 relate to cell proliferation rates?
In previous studies we have used the Ki67 antibody as an indirect marker of tumour cell growth fraction/ proliferative index (Nicholson et al., 1991 (Nicholson et al., , 1993 . This antibody detects a nuclear antigen which begins expression in G1 and continues through S, G2 and M phases of the cell cycle, but is not expressed in G0 (Gerdes et al., 1984) . The studies of our group, and others, have demonstrated a relationship between elevated Ki67 levels and short disease free interval and survival, EGFR positivity and loss of endocrine response in ER positive disease (Nicholson et al., 1993 . If the elevated expression of c-erbB3 and cerbB4 were involved in directing proliferation, then one would predict increased Ki67 levels in tumours positive for their mRNAs. This was not found to be the case. If anything, our immunocytochemical analysis of c-erbB3 demonstrated a non-signi®cant trend for highly c-erbB3 positive tumours to exhibit the lowest Ki67 levels. Importantly, examination of the expression of c-erbB3 using both RT ± PCR and immunocytochemistry in a small series of normal breast structures within the current study (Nicholson, unpublished) , and elsewhere (Rajkumar and Gullick, 1994) , has identi®ed that they frequently show high levels of c-erbB3, a feature also prominent in ER positive endocrine responsive breast cancers and notably contrasting the diminished signal associated with ER negativity. Elevated c-erbB3 expression in cancer cells particularly in ER positive tumours could therefore represent a dierentiated feature. In this light, it is noteworthy that aheregulin, a ligand for c-erbB3/c-erbB4 receptors, is also more likely to be elevated in ER positive disease (Knowlden and Nicholson, in preparation) and has been shown to initiate cellular dierentiation in breast cancer cells in vitro (Bacus et al., 1992 (Bacus et al., , 1993 . Indeed, high concentrations of c-erbB3/c-erbB4 ligands, may even result in a parallel inhibition of cellular proliferation (Bacus et al., 1992; Grunt et al., 1995) . Although there is clearly substantial overlap of the expression of individual erbB family members within the breast cancer population, the dierential eects of c-erbB3/cerbB4 and the EGFR may result from the ability of cerbB3 to eciently recruit PI3 Kinase (Solto et al., 1994; Fedi et al., 1994; Prigent and Gullick, 1994) and hence pro®ciently activate additional signal transduction pathways to those employed by EGFR. Relative availabilities of ligands, receptors and secondary pathways would appear to critically alter the proliferation/dierentiation status of breast tumours. In what manner do the cellular levels of c-erbB3 relate to endocrine response?
Once again the data in the present study identify that the cellular behaviour associated with c-erbB3 expression is divergent from that previously linked to the EGFR (and c-erbB2), in that elevated c-erbB3 expression in the sub-group of ER positive tumours appears to be a favourable predictor of endocrine response. Thus, over 80% of patients with ER positive tumours expressing the highest level of c-erbB3 derived measurable clinical bene®t from endocrine therapy (i.e. objective response or static disease; Table 3b ). This should not, however, necessarily be taken to mean that elevated c-erbB3 is responsible for the endocrine sensitivity of breast cancer, since its expression in ER negative tumours does not promote a similar responsive phenotype. Indeed, our recent clinical studies have failed to show any time dependent alteration in c-erbB3 levels in patients receiving the endocrine agent tamoxifen, nor are they suppressed in tumour specimens removed from patients who have developed acquired endocrine resistance (Robertson et al., in preparation) . These data suggest that c-erbB3, and possibly c-erbB4, are involved in aspects of tumour cell dierentiation, rather than in directing cellular growth patterns. Furthermore, although our study does not address the transforming ability of c-erbB3 (or cerbB4), which has previously been shown to be greatly enhanced by the co-expression with c-erbB2 or EGFR in ®broblasts (Alimandi et al., 1995; Wallasch et al., 1995) , the detection of c-erbB3 (mRNA and protein) in endocrine sensitive cancers at levels equivalent to those seen in normal breast tissue (albeit cancer associated) would not support a direct transforming role for cerbB3.
In conclusion, our presented observations suggest there is no causal relationship between c-erbB3 and/or c-erbB4 and tumour proliferation. We hypothesise, however, that there may be a role for c-erbB3 and cerbB4 in tumour dierentiation, based on indirect evidence of similar high levels of c-erbB3 expression in normal breast ducts and/or lobules as in tumour cells of ER positive cancers. We believe the results of the present study do not support the view that overexpression of any member of the type I tyrosine kinase receptor family can potentially enhance steroidautonomous tumour proliferation (Earp et al., 1995) and thus endocrine insensitivity.
Materials and methods

Tumour specimens
Two groups of breast tumours were used in the present study. First, a group, of histologically-proven breast cancers were excised from 47 patients presenting between 1987 ± 1989. In addition, seven tumour-associated normal breast specimens from this series were identi®ed. Representative tissues samples were snap frozen in liquid nitrogen, and each frozen sample was subsequently divided for RNA isolation before transportation on dry ice to the Tenovus Cancer Research Centre where they were stored at 7708C
In the second group, a series of 89 primary tumours from patients with histologically-proven breast cancer presenting for surgery at the City Hospital, Nottingham during the period 1984 ± 1987. Representative tissues samples from these 89 samples were either ®xed routinely in 4% formal saline and embedded in paran or snap frozen in liquid nitrogen. Each frozen sample was embedded in OCT medium for immunocytochemistry. No patient had previously received any form of adjuvant endocrine or cytotoxic therapy. All patients subsequently received systemic endocrine therapy either for locally advanced primary tumours (minimum diameter 5 cm) or for local or distant recurrences. Pre-or perimenopausal patients received the luteinizing hormonereleasing hormone (LH-RH) agonist goserelin (Zoladex R , 3.6 mg depot/28 days) alone (n=6) or in combination with the antioestrogen tamoxifen (Nolvadex R , 20 mg twice daily n=17), while the majority of postmenopausal women received tamoxifen (20 mg twice daily n=60). Also three postmenopausal women received the progestin, Megace (160 mg twice daily) and two patients received chemotherapy. Patients were assessed for responsive or progressive disease by UICC criteria (Hayward et al., 1977) . As recommended by the British Breast Group, patients were only assessed as having responsive and static disease after a minimum duration of therapy of 6 months (British Breast Group, 1974) .
First strand synthesis cDNA
Total RNA from each of the 47 tumours of group 1 and also from the seven tumour-associated normal breast specimens was isolated as described (Manning et al., 1995) and was reverse transcribed with random hexamers (RH) as described by O'Brian et al., (1991) . Brie¯y, 7 ml of RNase/DNase free sterile water (Baxter Health Care Ltd, Norfolk, UK), containing 1 mg of total RNA from each sample was added to a reaction mixture consisting of RH (Boehringer Mannheim Ltd, East Sussex, UK) (10 mM), dNTPs (0.625 mM) of each, 16PCR buer (10 mM Tris-HCl pH 8.3, 50 mM KCl, 1.5 mM MgCl 2 and 0.001% w/v gelatin) and dithiothreitol (0.01 M). A negative reverse transcription (7ve RT) control tube (lacking sample RNA) was also included to check for contamination. All mixes were denatured at 958C for 5 min and cooled rapidly on ice, before the addition of RNase inhibitor (25 units, Promega Ltd, Southampton, UK) and MMLV reverse transcriptase (Gibco/BRL, Life Technologies, Basingstoke, UK; 200 units), giving a ®nal volume of 20 ml. Reaction mixes were then incubated for 10 min at room temperature, reverse transcribed for 40 min at 428C, and ®nally heated at 958C for 5 min to terminate the reaction.
Simultaneous PCR of ER, EGFR, c-erbB3 and c-erbB4 cDNA
Simultaneous PCR ampli®cation was subsequently carried out on the reverse transcribed material with either ER, EGFR, c-erbB3 or c-erbB4 speci®c primers in combination with aactin primers as an internal control, using optimised conditions as described previously by Knowlden et al. (1997) . Two negative controls were included to check for contamination of the reaction mix, (i.e. negative PCR control lacking cDNA and a 7RT control lacking RNA). The aactin primers were included to verify sample-tosample uniformity under RT ± PCR reaction conditions and to monitor for degradation of mRNA and recovery of cDNA. The`mastermix' solution comprised sterile pure RNase/DNase free water, primers for ER, EGFR, c-erbB3 and c-erbB4 at a concentration of 0.5 mM and 0.125 mM for aactin, 0.2 mM dNTPs, 16PCR buer, 0.01 M dithiothreitol and 0.2 U Taq polymerase (Bioline Ltd, London, UK). Primers for ER, EGFR and aactin were as published (Fuqua et al., 1990; Frye et al., 1989; O'Brian et al., 1991; respectively) . Primers for c-erbB3 and c-erbB4 were selected using the primer program version 0.5 (Whitehead Institute, MIT). All primers synthesised are listed below:
5'-GGT GCT GGG CTT GCT TTT-3' 3' c-erbB3 5'-CGT GGC TGG AGT TGG TGT TA-3' 2 5' c-erbB4 5'-TGT GAG AAG ATG GAA GAT GGC-3' 3' c-erbB4
5'-GTT GTG GTA AAG TGG AAT GGC-3'
The reactions were carried out on a PTC-100 thermocycler (Genetic Research Instrumentation Ltd, Essex, UK) with the following thermal pro®le previously shown to be generally eective in breast cancer (Knowlden et al., 1997) : One cycle of 3 min at 958C (denaturing), 1 min at 558C (annealing) and 1 min at 728C (extension), followed by 25 cycles, with 30 s at 948C, 1 min at 558C and 1 min at 728C and a ®nal of 1 min at 958C, 1 min at 558C and 10 min at 728C. Ampli®ed DNA fragments were subsequently electrophoresed through a 3% w/v agarose gel comprising 2% w/v nusieve/1% w/v normal agarose, visualised under UV illumination, photographed and scanned densitometrically. Data obtained were normalised in respect to aactin densitometric values. For ER mRNA analysis, two cut-o points were applied to the tumour samples: 50.15, the lower level of signal detection following densitometry and 0.7, the mean signal value. For the EGFR, c-erbB3 and c-erbB4 RT ± PCR assays, the mean value was chosen as a single cut-o point (50.17, 50.27 and 50.35 respectively).
Con®dence in the optimised RT ± PCR procedure for the detection of c-erbB3 mRNA was initially tested on a series of cell monolayers reported in the literature as positive (ZR75.1, MCF-7, MDA 453; Lemoine et al., 1992; Chan et al., 1995; Rajkumar et al., 1995) or negative (MDA 231, A431; Rajkumar and Gullick, 1994) respectively for c-erbB3 protein or mRNA. Furthermore, assay conditions were carefully optimized by performing simultaneous RT ± PCR of each speci®c primer in combination with aactin on 10 of the breast cancer samples using a range of cycle numbers (20 ± 32) and using conditions identical to those described previously (Knowlden et al., 1997) . In addition, the reproducibility of the developed procedure (Knowlden et al., 1997) was examined further by performing simultaneous RT ± PCR on a smaller sub-group of the 47 tumour cDNA samples using speci®c primers c-erbB3 and c-erbB4 in combination with aactin primers. The assay was carried out on three consecutively days and the intensity of the resultant PCR products following gel elecrophoresis were compared.
Immunocytochemical assessment ER, EGFR and Ki67
Both groups of tumour samples were embedded in OCT and immunocytochemically assayed for ER, EGFR and Ki67 as previously described Nicholson et al., 1991 Nicholson et al., , 1993 . Tumour epithelial cell nuclear immunostaining for ER and Ki67 and membrane staining for EGFR were subsequently semi-quanti®ed in each sample by HScore analysis (McCarty et al., 1985) . Previously established values Nicholson et al., 1991) were subsequently employed as the positivity cut-o points for statistical analysis.
c-erbB3 protein Immunocytochemical assay The proficiency of the optimized immunocytochemical assay using the RTJ1 antibody (Rajkumar et al., 1993) for detection of c-erbB3 was initially tested on a series of 3.7% formaldehyde-®xed cell monolayers reported in the literature as positive (ZR75.1, MCF-7, MDA 453; Lemoine et al., 1992; Rajkumar et al., 1995) or negative (MDA 231, A431 Rajkumar and Gullick, 1994) respectively for c-erbB3 protein. Further con®dence in the speci®city of the assay for c-erbB3 was derived from control sections of each clinical sample which were incubated with a dilution of RTJ1 primary antibody matched to that of the paired tests but pre-absorbed for 5 h with appropriate c-erbB3 peptide (i.e. one part antibody: three parts peptide).
Following the initial assay validation, wax sections from each tumour sample from the group 2 series of patients were dewaxed using xylene treatment (265 min); they were then rehydrated through graded ethanols to PBS. Endogenous peroxidases were destroyed using 0.5% hydrogen peroxide prepared in methanol (10 min), running tap water for 5 min, rinsing the slides in PBS (265 min). All slides were enzymatically-digested for 25 min at 378C using a bath of 0.02% pronase E (Sigma, Poole, UK) freshly prepared in prewarmed PBS. Digestion was terminated by thoroughly rinsing the slides in running tap water (5 min) and then by soaking in PBS (265 min). Excess buer was removed from all the slides by carefully wiping round, and they were then blocked for 20 min using 1% Marvel (non-milk fat protein) powder prepared in PBS. Test slides were then incubated overnight in a sealed humidity chamber at room temperature with monoclonal mouse primary antibody RTJ1; raised to a synthetic peptide from the cytoplasmic domain of the human c-erbB3 protein (Rajkumar et al., 1993) , (1/4 supernatant) prepared in PBS. Following PBS rinsing (463 min), the slides were covered for 1 h with a biotinylated anti mouse antibody (`Monoclonal Mouse Linking Reagent', Immustain Streptavidin-Biotin Universal kit, Euro-DPC, Llanberis, UK) and further rinsed in PBS (463 min) before ®nally incubating for 1 h with horseradish peroxidase-conjugated streptavidin solution (`Streptavidin Enzyme Label', Immustain Streptavidin-Biotin Universal kit, Euro-DPC) and PBS rinsing. Signal detection was carried out for 10 min with freshly prepared diaminobenzidine tetrahydrochloride/hydrogen peroxide chromogen (Abbott Diagnostics ER-ICA kit, Maidenhead, UK). Following rinsing in distilled water (262 min), the resultant signal was enhanced for 7 min using 0.5% CuSO 4 .5H 2 0 prepared in 0.85% NaCl. The slides were washed in distilled water and lightly counterstained for 4 min using 0.5% methyl green (aqueous). They were then dehydrated brie¯y through distilled water and graded ethanols, before air-drying prior to clearing in xylene and coverslipping using DPX mountant.
Immunocytochemical c-erbB3 assessment and statistical analysis: Membrane c-erbB3 immunostaining in the panel of cell lines used to validate the assay was assessed. Similarly, tumour epithelial cell immunostaining in clinical specimens was predominantly membrane-located for the cerbB3 protein with negligible c-erbB3 immunostaining found in stromal elements of the tumour specimens. All membrane staining was assessed by two personnel (Gee JMW, Nicholson RI) using a dual-viewing attachment to an Olympus BH-2 light microscope at an ocular magnification of 640. Staining was noted in areas of associatednormal breast tissue in the clinical samples, but this was excluded from the tumour assessment. Any specimens showing background staining on control slides or too few tumour epithelial cells were rejected. In addition, assay performance was monitored by the inclusion of a breast cancer positive control section of known immunostaining percentage and intensity. Both the cell staining intensity and percentage positivity (minimum of 2000 tumour cells evaluated) were assessed for all the clinical specimens and cell lines examined. These data were used to construct a tumour cell staining index, the HScore, for the c-erbB3 protein in every sample as follows:
HScore=(% cells staining weakly/100)61+ (% cells staining moderately/100)62+ (% cells staining strongly/100)63. 
Statistical analysis
Comparative analysis of data was performed using Fisher's Exact Test and w 2 statistic. Spearman Rank Correlation Test was employed to determine the degree of association between the protein HScore/normalised mRNA levels of all examined variables. The Mann ± Whitney U test was employed to compare median values between certain groups. Overall survival between patient groups were compared using the Generalized Wilcoxon Test.
